Financial Performance - Company reported a total revenue of 414 million yuan for the first half of 2025, representing a year-on-year increase of 21.74% [1] - Net profit attributable to shareholders reached 63.31 million yuan, up 40.52% year-on-year [1] - Gross margin stood at 72.06%, a slight decrease of 0.5% compared to the previous year, while net margin increased by 23.4% to 15.86% [1] - Total operating expenses were 132 million yuan, accounting for 32.0% of revenue, down 5.96% year-on-year [1] Key Financial Metrics - Earnings per share (EPS) increased by 41.07% to 0.16 yuan [1] - Operating cash flow per share rose significantly by 80.01% to 0.06 yuan [1] - The company's return on invested capital (ROIC) was 4.31% last year, indicating a relatively weak capital return [3] - The company’s historical median ROIC since listing is 10.6%, with the worst year being 2023 at 3.31% [3] Strategic Initiatives - Company emphasizes a customer-centric marketing strategy, focusing on building strategic partnerships with key clients [5] - Revenue from strategic clients in the biopharmaceutical sector accounted for approximately 50% of sales in 2024, showcasing the effectiveness of deepening strategic collaborations [5] - The company aims to enhance customer satisfaction and leverage strategic client relationships to drive revenue growth [5] Fund Holdings - The largest fund holding in the company is from Huatai-PineBridge, with a total of 1.0052 million shares newly entered into the top ten holdings [4] - Other funds that have newly entered the top ten holdings include Bosera Health Growth and Bosera Health Life, indicating growing institutional interest [4]